Carna Biosciences, Inc.

National Cancer Center

Kanebo, Limited

Mychunter Therapeutics, Inc.

Hideki Moriyama

Masaaki Sawa

Tesshi Yamada

Yuko Uno

Takahiro Tsukida

Kenji Nakamura

Shinichiro Nishimura

Tadayuki Saito

Hirosato Kondo

Shigeki Kashimoto

Koichi Yokota

Hiroshi Ohmoto

Miki Shitashige

Mariko Hatakeyama

Yukihisa Wada

Takao Kiyoi

Toshio Achiha

Kiriko Kurokawa

Yusuke Kawase

The present invention provides a quinazoline derivative represented by the following formula (I): wherein Rand Rrepresent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/&#x3b2;-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.

Quinazoline derivative

The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R, R, Rand Q are as defined in the specification), or a pharmaceutically acceptable salt thereof. 

Bicyclic thiazole compounds

A novel azasugar derivative, and a drug containing the same as an active ingredient are disclosed. The drug is useful for treatment of keratinocyte-proliferative diseases.

Azasugar derivative and drug containing the same as the active ingredient

Fucose derivatives, drugs containing the same as active ingredient, and

Growing community of inventors

Kobe, Japan

Hideki Moriyama